On July 20, 2026, the company received notice from Nasdaq that it failed to maintain the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until January 19, 2027, to regain compliance, with potential for an additional 180 d…
Oncolytics reported FDA regulatory engagement and rapid enrollment progress for the randomized REO 033 trial, advancing a potential registrational pathway for pelareorep.Key Highlights:Original SEC Filing: ONCOLYTICS BIOTECH INC [ ONCY ] - 8-K - Jul. 13, 2026This is an AI-powered summary. It may co…
Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centersCompany to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial designPart B wil…
